非誠(chéng)勿擾與惡性黑色素瘤

上傳人:san****019 文檔編號(hào):20624833 上傳時(shí)間:2021-04-05 格式:PPT 頁(yè)數(shù):31 大?。?.22MB
收藏 版權(quán)申訴 舉報(bào) 下載
非誠(chéng)勿擾與惡性黑色素瘤_第1頁(yè)
第1頁(yè) / 共31頁(yè)
非誠(chéng)勿擾與惡性黑色素瘤_第2頁(yè)
第2頁(yè) / 共31頁(yè)
非誠(chéng)勿擾與惡性黑色素瘤_第3頁(yè)
第3頁(yè) / 共31頁(yè)

下載文檔到電腦,查找使用更方便

9.9 積分

下載資源

還剩頁(yè)未讀,繼續(xù)閱讀

資源描述:

《非誠(chéng)勿擾與惡性黑色素瘤》由會(huì)員分享,可在線閱讀,更多相關(guān)《非誠(chéng)勿擾與惡性黑色素瘤(31頁(yè)珍藏版)》請(qǐng)?jiān)谘b配圖網(wǎng)上搜索。

1、“ 非 誠(chéng) 勿 擾 ” 與 惡 性 黑 色 素 瘤 catalogue What is malignant melanoma? Melanoma triggers and causes Primary sites Clinical characteristics Early clinical performance Late-stage clinical manifestations Pathological type Treatment 2010 melanoma field progress review What is malignant melanoma? Malignant mela

2、noma, also known as melanoma, is the origin of epidermal melanocyte or nevus of malignant tumors. The disease can be seen at any age, more seen in middle- aged and older, women slightly more than men. Melanoma triggers and causes Air pollution To pursue beauty The lack of medicine knowledge Immune d

3、eficiency Abusing the estrogen drugs Malignant transformation of black mole Racial genetic factors Trauma and chronic stimulation factors Air pollution Harmful ultraviolet light and some harmful material in the air make a difference of human skin, causing melanocyte abnormal expression, trigger mela

4、noma. Many people in order to pursue the clean skin to use chemical cosmetics, skin pollution caused by chemical, even someone with chemical mordant purify skin a mole, stimulates the excessive proliferation melanocyte. To pursue beauty Racial genetic factors Malignant melanoma occur in the white ra

5、ce. For the incidence of world each year to less than 1 2/10 million, but Australias Queensland annual incidence of 16/10 million population, it is the worlds leading high incidence of malignant melanoma. Africa and Asian people rarely have the sickness. Primary sites Malignant melanoma 90 % occurs

6、in the skin, the most common in the back, metal- studded ,leg, foot, toe, nail bed, scalp and so on ; a few occurs in vulvae, digestive tract and eyes. Eye lesions and Oral lesions 脈絡(luò)膜黑色素瘤 口腔黑色素瘤 Generally speaking moles surface is smooth, melanoma of surface is coarser. If the surface is smooth, an

7、d suddenly becomes coarse or , we should pay attention to it. Clinical characteristics Ulceration not only is one of the important melanoma clinical manifestations which is different from mole, but also has the meaning of prognosis than no ulcer. Patients of malignant melanoma generally are the old;

8、 the youth or children melanoma are rare . Early clinical performance Color: a mole increase in size, pigment or darker or lighter, a mole deepen, shiny, appear color changed . Edge: a mole to radiate out in moles expansion, appear around uneven indented change; become irregular or appear satellite

9、form small a mole, or several birthmark fusion, the surface concavo-convex inequality . Surface: rough; Often coarse and accompanied by scale form or flake desquamation. Sometimes have the drainage or ooze blood, higher lesions can face . Lesions surrounding skin :can appear edema or lose skin gloss

10、 or become white, gray. Kakesthesia: a mole without itching or discomfort pain. regional lymph node enlargement, faintly visible blue-black . 早期臨床表現(xiàn) Late-stage clinical manifestations Special type : a small nodular lesion site, the boundary clear, no coated, tan-white or grey- blue, quality of a mat

11、erial is solid. Freckles type :more from the primary lesions malignant freckles ; surface was flat; the edge great irregularity ; the epidermis of tumor block with freckles samples , this type often occur on elderly facial freckles lesions , which is relatively rare. Spread type : its appearance is

12、shallow eczema kind, and its jagged edge is irregular ,with black, grey and pink disorderly color on the surface . Nodular type: tumor nodules are out of the skin surface; the color is dark brown, gray red and rarely colorless. Bump surface is shown more cauliflower shape, polypoid or bacteria shape

13、, often happen ulcers . Pathological type Superficial expandable type: about 70%, it is visible at surface anywhere ; go along the surface to expand, and then expand to the depth , called the vertical development. nodular type: about 15%,vertical development; penetrate to subcutaneous tissue; prone

14、to lymph node metastases; even more deadly. Ephelides type :about 5%,it primary occur in old people facial skin where black freckles long stand; this type do horizontal growth and enlarge 2cm 3cm or more around. Extremity black mole type: about 10% that happens at palms, foot, nail bed and mucous me

15、mbranes. Treatment Surgical treatment : early circumscribed primary foci should be carried out extensively; the scope should be apart from the primary foci 3 5cm ; the primary foci should be excised to subcutaneous tissue and muscle membrane ; when touch the lymph node enlargement, generally speakin

16、g should make lymph node clean; after the operation ,adjuvant chemotherapy and immune therapy is necessary . Biological immune therapy :biological immune therapy via the various biological agents and biotechnology means to enhance immunity and anti- cancer ability to suppress and kill cancer cells;

17、at present, immune cells such as DC cells, CIK cell have applied to clinical therapy, which gains good effects; biological immune therapy is the most effective, security adjuvant therapies. 人類(lèi)黑色素瘤抗原 Radiotherapy: In addition to some very early freckles type of malignant melanoma are effective, other

18、 primary foci generally have poor curative effect. So we did not use radiation therapy to cure the primary foci, and metastasis adopt radiotherapy. Endocrine therapy : anti-estrogen drugs make some cases even other drug treatment failure cases get curative effect, and make the illness to alleviate.

19、Chemical treatment : Single drug: )亞硝脲類(lèi)藥物 : have certain effect of melanoma. 氮烯咪胺 (DTIC): DTIC has made the treatment of melanoma forward one step, become the most widely used drugs. Each dose for 350mg/m2, repeat 6 days, 28 days for one period of treatment, efficient rate is 35%. Combination: combi

20、nation can improve the efficient, reduce toxicity reaction. DAV case (DTIc、 ACNu、 VCR): the first choice for melanoma chemotherapy regimens. The preparation method: DTIcloo 200mg, 5ACNUl00mgiv d1VCR 2mg iv d1 21 days, each iv d1 repeated 1 time. DDBT case (DTIC、 DDP、 BCNU、 TAM) Method:DTIC220mg/m2,

21、I.V. d1 3/3w, DDP 25mg/m2, i.v.gtt d1 3w, BCNUl 50mg/m2, I.V. d1/6w, TAM 10mgPO, 2 / d. Efficient rate is 52.5%. CBD case (CCNU、 BLM、 DDP) Method: CCNU 80mg/m2, oral, d1/6w, BLMl 5u/m2, I.V. d3 7/6w, DDP 40mg/m2, I.V. d8/6w. Efficient rate is 48%. 2010 melanoma field progress review melanoma treatme

22、nt finally usher a silver lining Resistance to CTLA - 4 single resistance against genetic mutations and (B - RAF and C - KIT) small molecular targeted drugs ,which prolong the survival of advanced melanoma patients and achieve remarkable breakthrough. It is possible for the treatment of advanced mel

23、anoma patients bring thorough revolution. In advanced melanoma chemotherapy , it is still the gold standard that Dacarbazine(達(dá)卡巴嗪 ), but efficient rate is only 8 % 12%. Many biological chemotherapy or more medicine chemotherapy period clinical studies has showed high efficient rate. But period contr

24、olled study of overall survival shows havent exceeded single-agent Dacarbazine(達(dá)卡巴嗪 ). American ODay report a randomized controlled clinical research about period, its result has significance. The study proved targeted immune therapy drugs Ipilimumab to prolong period melanoma patients survival. Ipilimumab blockade the combination CTLA4 with B7 which can remove anti- tumor immunosuppression, thus ,it really mobilize specificity anti-tumor immune response. THE END!

展開(kāi)閱讀全文
溫馨提示:
1: 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
2: 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
3.本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
5. 裝配圖網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

相關(guān)資源

更多
正為您匹配相似的精品文檔
關(guān)于我們 - 網(wǎng)站聲明 - 網(wǎng)站地圖 - 資源地圖 - 友情鏈接 - 網(wǎng)站客服 - 聯(lián)系我們

copyright@ 2023-2025  zhuangpeitu.com 裝配圖網(wǎng)版權(quán)所有   聯(lián)系電話:18123376007

備案號(hào):ICP2024067431號(hào)-1 川公網(wǎng)安備51140202000466號(hào)


本站為文檔C2C交易模式,即用戶上傳的文檔直接被用戶下載,本站只是中間服務(wù)平臺(tái),本站所有文檔下載所得的收益歸上傳人(含作者)所有。裝配圖網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)上載內(nèi)容本身不做任何修改或編輯。若文檔所含內(nèi)容侵犯了您的版權(quán)或隱私,請(qǐng)立即通知裝配圖網(wǎng),我們立即給予刪除!